TFFP Tff Pharmaceuticals

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally.

Company profile

Glenn R. Mattes
Fiscal year end
TFF Pharmaceuticals Australia Pty Ltd ...
IRS number

TFFP stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


12 Aug 21
19 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 52.07M 52.07M 52.07M 52.07M 52.07M 52.07M
Cash burn (monthly) 2M (positive/no burn) 1.7M 2M 1.96M 1.83M
Cash used (since last report) 7.31M n/a 6.24M 7.33M 7.19M 6.71M
Cash remaining 44.76M n/a 45.83M 44.74M 44.88M 45.36M
Runway (months of cash) 22.4 n/a 26.9 22.4 22.9 24.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Sep 21 Christopher Cano Stock Option Common Stock Grant Acquire A No No 7.93 43,000 340.99K 200,000
16 Sep 21 Kirk Allen Coleman Common Stock Buy Acquire P No No 7.3 1,000 7.3K 2,000
16 Sep 21 Glenn R. Mattes Common Stock Buy Acquire P No No 7.1 10,000 71K 20,000
19 May 21 Fairbairn Malcolm Common Stock Buy Acquire P Yes No 8.95 10,000 89.5K 10,000
18 May 21 Thurman Randy H Common Stock Buy Acquire P No No 9.4 1,050 9.87K 1,050

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

34.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 61 64 -4.7%
Opened positions 12 24 -50.0%
Closed positions 15 8 +87.5%
Increased positions 21 19 +10.5%
Reduced positions 19 11 +72.7%
13F shares
Current Prev Q Change
Total value 96.74M 138.31M -30.1%
Total shares 8.62M 10.03M -14.0%
Total puts 166.4K 132.9K +25.2%
Total calls 45.5K 133.7K -66.0%
Total put/call ratio 3.7 1.0 +267.9%
Largest owners
Shares Value Change
Lung Therapeutics 2.95M $42.24M 0.0%
DRW Securities 1M $9.61M +94.8%
Vanguard 771.85K $7.42M +10.8%
Gagnon Securities 458.6K $4.41M +21.3%
Nantahala Capital Management 367.82K $3.54M -3.9%
BLK Blackrock 261.51K $2.51M -8.2%
Carlson Capital L P 215K $2.07M +26.5%
Granite Point Capital Management 210K $2.02M 0.0%
Renaissance Technologies 182.7K $1.76M +182.4%
Gagnon Advisors 176.47K $1.7M 0.0%
Largest transactions
Shares Bought/sold Change
Corriente Advisors 0 -1.57M EXIT
DRW Securities 1M +486.6K +94.8%
Altium Capital Management 0 -269.69K EXIT
Hudson Bay Capital Management 100K -255K -71.8%
Millennium Management 113.26K -126.41K -52.7%
Renaissance Technologies 182.7K +118K +182.4%
Princeton Capital Management 110.28K +110.28K NEW
Two Sigma Investments 94.28K +94.28K NEW
Precept Management 15K -92.3K -86.0%
Gagnon Securities 458.6K +80.63K +21.3%

Financial report summary

Management Discussion
  • We were formed in January 2018 and have not commenced revenue-producing operations. To date, our operations have consisted of the development and early-stage testing of our initial product candidates. In connection with our organization on January 24, 2018, we entered into a Contribution and Subscription Agreement with Lung Therapeutics, Inc., or LTI, our former parent, pursuant to which we agreed to acquire from LTI certain of LTI’s non-core intellectual property rights and other assets, or the Acquired Assets, all of which relate to our Thin Film Freezing technology. We closed on the acquisition of the Acquired Assets concurrent with the close of the initial Series A preferred stock financing in March 2018.
Content analysis
H.S. sophomore Avg
New words: academic, adjust, Albert, analogy, array, broad, Codification, College, CRADA, customer, default, delinquent, derived, distinct, Einstein, Georgia, half, influenza, JDA, jointly, lieu, offset, ongoing, originally, ownership, partnership, percentage, pharma, prepaid, prevent, pro, Put, rata, recruitment, reduction, refund, refundable, reimbursable, reimbursement, relevant, remote, scope, selected, slower, sublicensable, taxable, Taxation, therapeutic, transaction, travel, USAMRIID, VSV
Removed: Brisbane, declared, delayed, file, final, IPO, Melbourne, opened, partial, Queensland, registered, resurgence, site, Victoria